Fidia SpA represents values of innovation, excellence, and commitment in its corporate philosophy. The company prioritizes research and development, aiming to bring advanced solutions to the medical and biotech sectors. Fidia SpA focuses on providing high-quality products and services, striving to meet the evolving demands of its customers. With a strong emphasis on sustainability and social responsibility, Fidia SpA contributes to a healthier future through its innovative pharmaceutical and biomedical technologies. As a leading company in its field, Fidia SpA consistently delivers value to its stakeholders while upholding its commitment to scientific progress and ethical business practices.

Fidia SpA is primarily present in various countries and regions globally. With its headquarters in Italy, Fidia SpA has established a strong presence within Europe. Additionally, it has expanded its reach to other regions, including North America, Latin America, Asia-Pacific, and the Middle East. Fidia SpA's international footprint allows the company to serve a diverse range of markets and customers, fostering growth and development on a global scale.

Fidia SpA has accomplished several significant milestones throughout its history. The company's commitment to excellence and innovation has led to remarkable achievements. Some notable milestones of Fidia SpA include successful development and commercialization of groundbreaking medical solutions, expansion into new markets, strategic collaborations with key industry players, and consistent growth in revenue and market share. Fidia SpA's dedication to research and development, along with its strong focus on customer satisfaction, has positioned the company as a leading player in the global healthcare industry.

Fidia SpA, a renowned Italian company, has a rich history and background. Established in 1946, Fidia SpA specializes in the development and production of innovative pharmaceuticals and healthcare technologies. With a strong commitment to research and development, the company has made significant contributions to the field of biotechnology. Fidia SpA has a diverse portfolio of products, including hyaluronic acid-based therapies for osteoarthritis and wound care. Over the years, Fidia SpA has expanded its presence globally, collaborating with international partners and maintaining a strong focus on patient well-being. As a reputable player in the healthcare industry, Fidia SpA continues to strive for excellence and deliver cutting-edge solutions in the pharmaceutical and biotechnology sectors.

The main competitors of Fidia SpA in the market are other companies operating in the pharmaceutical industry. These competitors include renowned players such as Novartis, Pfizer, Roche, and GlaxoSmithKline. Fidia SpA faces stiff competition in the global market as these companies specialize in the development and production of innovative medicines, medical devices, and innovative therapies. This competitive landscape challenges Fidia SpA to continuously focus on research and innovation, maintaining a strong market position, and offering unique value propositions for healthcare professionals and patients.

Fidia SpA operates primarily in the pharmaceutical and biotechnology industries.

Fidia SpA's business model revolves around the pharmaceutical industry. As a specialized research and development company, Fidia SpA focuses on the development and production of innovative drugs and medical devices. With a strong emphasis on biomaterials and hyaluronic acid-based therapies, Fidia SpA strives to improve patients' quality of life by addressing various medical conditions, including osteoarthritis and tissue regeneration. By leveraging its scientific expertise, cutting-edge technologies, and strategic partnerships, Fidia SpA remains committed to delivering high-quality, safe, and effective pharmaceutical solutions to patients globally.

Pašreizējais KGV Fidia SpA nevar tikt aprēķināts.

KUV šobrīd Fidia SpA nevar aprēķināt.

AlleAktien kvalitātes vērtējums Fidia SpA ir 3/10.

Pašreiz nevar aprēķināt apgrozījumu Fidia SpA.

Pašlaik peļņa Fidia SpA nevar tikt aprēķināta.

Fidia SpA aims to provide innovative solutions for the treatment of various diseases and injuries, focusing on the development and manufacturing of pharmaceuticals, medical devices, and cosmetic products. Through collaboration with international companies and research institutes, Fidia has a global influence on the pharmaceutical industry.

Fidia SpA izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Fidia SpA vai uzņēmums nedod dividendes.

Fidia SpA ISIN ir IT0001498481.

Fidia SpA WKN ir 589983.

Fidia SpA simbols ir FDA.MI.

Pēdējo 12 mēnešu laikā Fidia SpA maksāja dividendes 0,20 EUR apmērā. Tas atbilst aptuveni 98,04 % dividendes ražībai. Nākamajos 12 mēnešos Fidia SpA plāno maksāt dividendes 0 EUR apmērā.

Fidia SpA pašreizējā dividendu rentabilitāte ir 98,04 %.

Fidia SpA maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos jūnijs, jūnijs, jūnijs, augusts.

Fidia SpA pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

Fidia SpA tiek piešķirts nozarei "Industrija".

Lai saņemtu pēdējo dividendu Fidia SpA apmērā 0,2 EUR, kas tika izmaksāta 5.07.2017., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 3.07.2017..

Pēdējās dividendes izmaksa notika 5.07.2017..

Gadā 2023, Fidia SpA izmaksāja 0 EUR dividendes.

Fidia SpA dividendes tiek izmaksātas EUR.